E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

Biotechnology Market Sector
More Pages: Page: 1 2 3 4 5 6 (7) 8 9 10 11
NYSE:CURNeuralstem, Inc.
 Neuralstem is a biotechnology company focused on developing and commercializing human neural stem cell technology in the field of regenerative medicine. Co. focuses primarily on the field of Cell Therapy, which involves the development and commercialization of treatments based on transplanting human neural stem cells. As of Dec 31 2006, Co. has developed and maintains a portfolio of patents and patent applications that form the proprietary base for its research and development efforts in the area of neural stem cell research, and have ownership or exclusive licensing of four issued patents and 12 patent pending applications in the field of regenerative medicine and related technologies.
 Market CapDay's VolumeLast TradeChange
 $95M160,854$2.45-3.9216%
 
OTC PK:NTIINeurobiological Technologies, Inc.
 Neurobiological Technologies is a specialty biopharmaceutical company with knowledge in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. Co. is developing Viprinex, a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. Viprinex is a reperfusion agent that has been well characterized and clinically evaluated in multiple trials for acute ischemic stroke. Also known as ancrod, Viprinex is an enzyme derived from the venom of the Malayan pit viper.
 Market CapDay's VolumeLast TradeChange
 -0$0.130.0%
 
NASDAQ:NBIXNEUROCRINE BIOSCNCE
 Neurocrine Biosciences discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Co.'s product candidates address several pharmaceutical markets including insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes and other neurological as well as endocrine related diseases and disorders. At Dec 31 2006, Co. had nine programs in various stages of research and development, including six programs in clinical development, and had entered into a collaboration for one of its programs. Co.'s key clinical development program, indiplon, is a drug for the treatment of insomnia.
 Market CapDay's VolumeLast TradeChange
 -594,214$6.47-0.7669%
 
NASDAQ:HCTLNEXGEN BIOFUELS
 Healthcare Technologies specializes in the development, manufacture and marketing of clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point of care sites in Israel and worldwide. Co. is also engaged in the research and development, production and marketing of molecular biology based gene screening tools for the detection of certain gene-associated disorders in humans, including prenatal testing for diseases such as cystic fibrosis, gaucher and other diseases and testing for predisposition to diseases such as breast, ovarian and colon cancer, thrombosis and certain cardiovascular diseases.
 Market CapDay's VolumeLast TradeChange
 $7M0$0.860.0%
 
NASDAQ:NFLDNORTHFIELD LABS
 Northfield Laboratories is engaged in the research, development, testing, manufacture, marketing and distribution of a hemoglobin-based oxygen-carrying red blood cell substitute for the treatment of urgent, large volume blood loss in trauma and resultant surgical settings. Co.'s primary product, PolyHeme , is a human hemoglobin-based oxygen-carrying red blood cell substitute in development for the treatment of life-threatening blood loss when an oxygen-carrying fluid is required and red blood cells are not available. Co.'s PolyHeme is designed for rapid, massive infusion, which is the way blood is transfused in trauma patients.
 Market CapDay's VolumeLast TradeChange
 -0$0.11160.0%
 
OTC PK:NSTRNorthstar Neuroscience, Inc.
 Northstar Neuroscience is a medical device company focused on developing and commercializing neurostimulation therapies for a range of neurological diseases and disorders. Co.'s proprietary system, the Renova Cortical Stimulation System, is designed to deliver targeted electrical stimulation to the outermost layer of the brain in a process referred to as cortical stimulation. Co.'s initial product candidate, the Renova-ST Cortical Stimulation System, is designed to enhance recovery of hand and arm motor function in patients who have suffered a stroke.
 Market CapDay's VolumeLast TradeChange
 $41M0$0.030.0%
 
NASDAQ:NVAXNOVAVAX
 Novavax is a biopharmaceutical company that develops vaccines for infectious diseases. Co. uses its proprietary virus-like particle (VLP) and Novasome adjuvant technologies to develop vaccines against H5N1, H9N2 and other subtypes of avian influenza with pandemic potential; viral diseases; and human seasonal influenza. Co. is also focuses on developing its VLP technology into vaccines for the prevention of HIV-1/AIDS and SARS. At Dec 31 2006, Co. has developed vaccines to prevent hepatitis caused by the Hepatitis E Virus, in collaboration with National Institute of Allergy and Infectious Disease; Walter Reed Army Institute for Research; GlaxoSmithKline Pharmaceuticals; and Wave Biotech.
 Market CapDay's VolumeLast TradeChange
 -528,316$2.28+0.4405%
 
NASDAQ:NPSPNPS PHARMACEUTICALS
 NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecule drugs and recombinant proteins. Co.'s portfolio of approved drugs and product candidates are primarily for the treatment of bone and mineral disorders, gastrointestinal disorders and central nervous system disorders. As at Dec 31 2006, Co.'s products consist of one U.S. Food and Drug Administration approved product, another product candidate that has been granted marketing approval in Europe, a product candidate that is the subject of a pivotal Phase III clinical study, and other product candidates in various stages of clinical development and preclinical development.
 Market CapDay's VolumeLast TradeChange
 -314,731$7.16-1.7833%
 
NASDAQ:NUTRNUTRACEUTICAL INTL
 Nutraceutical International is an integrated manufacturer, marketer, distributor and retailer of branded nutritional supplements and other natural products sold primarily to and through domestic health and natural food stores. Internationally, Co. markets and distributes branded nutritional supplements and other natural products to and through health and natural product distributors and retailers. At Sep 30 2007, Co. sold branded nutritional supplements and other natural products under the trademarks including Solaray , KAL , Nature's Life , and Natural Balance , and publishes, prints and markets a line of natural health and lifestyle books and booklets under the name Woodland Publishing .
 Market CapDay's VolumeLast TradeChange
 $142M32,404$15.96-1.1765%
 
OTCBB:NXXINutrition 21, Inc.
 Nutrition 21 is a nutritional biosciences company that develops and markets proprietary and clinically-substantiated nutritional supplements and therapeutics that address significant age-related health care concerns, including obesity, insulin resistance, and joint health. At Aug 2006, Co. entered the omega-3 market through its acquisition of Iceland Health, Inc., besides continuing to focus on the research, development and commercialization of chromium-based nutrition products for use in improving the structure or function of the body, and in the prevention and treatment of metabolic diseases such as diabetes, depression and cardiovascular disease.
 Market CapDay's VolumeLast TradeChange
 -0$0.07750.0%
 
NASDAQ:NUVONuvelo, Inc.
 Nuvelo is a biopharmaceutical company that is engaged in the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapies. As of Dec 31 2006, Co.'s development pipeline included three acute cardiovascular programs, alfimeprase , recombinant nematode anticoagulant protein c2 ( rNAPc2 ) and NU172 , a direct thrombin inhibitor, as well as two oncology programs, rNAPc2 and stimulator of gastrointestinal epithelial cells, NU206 . In addition, Co. has two research programs, one focused on secreted proteins and the other focused on cancer antibody discovery.
 Market CapDay's VolumeLast TradeChange
 $81M0$0.220.0%
 
NASDAQ:NYMXNYMOX PHARMACEUTICL
 Nymox Pharmaceutical is a biopharmaceutical company engaged in the research and development of products for the aging population. Co. markets AlzheimAlert , a urinary test that aids physicians in the diagnosis of Alzheimer's disease. Co. also markets NicAlert and TobacAlert , tests that use urine or saliva to detect use of tobacco products. In addition, Co. develops therapeutics for the treatment of Alzheimer's disease, new treatment of urinary tract and other bacterial infections in humans, including a treatment for E-coli O157:H7 bacterial contamination in meat and other food and drink products.
 Market CapDay's VolumeLast TradeChange
 -101,654$4.28-3.3861%
 
OTCBB:OCTLOctillion Corp.
 Octillion, together with its wholly owned subsidiaries, is a technology incubator focused on the identification, acquisition, development and eventual commercialization of emerging technologies. Among Co.'s current research and development activities are the development of 1) a patent-pending technology that could adapt existing home and office glass windows into ones capable of generating electricity from solar energy without losing significant transparency or requiring major changes in manufacturing infrastructure, and 2) technologies and products for peripheral and optic nerve damage and nerve regeneration.
 Market CapDay's VolumeLast TradeChange
 $76M0$0.240.0%
 
NASDAQ:OMRIOmrix Biopharmaceuticals, Inc.
 Omrix Biopharmaceuticals is a commercial-stage biopharmaceutical company which develops and markets biological products. Co. utilizes its protein purification technology and manufacturing knowledge to develop biosurgical and passive immunotherapy products derived from human plasma. Its biosurgical product line includes products and product candidates used for hemostasis and other surgical applications. Meanwhile, Co.'s passive immunotherapy product line includes antibody-rich products and product candidates for immune deficiencies and infectious diseases treatment, including potential biodefense applications.
 Market CapDay's VolumeLast TradeChange
 -0$24.990.0%
 
OTC PK:ONCROncor, Inc.
 Co. develops, produces and markets cancer-oriented genetic probes, related reagents, molecular biology products, and diagnostic products. Co. is conducting preclinical studies for detection tests for certain leukemias, bladder cancer, lung cancer and certain blood cancers. Co. is also developing or improving genetic test systems for the detection and management of significant life-threatening cancers, including breast cancer, bladder cancer, lung cancer and certain blood cancers.
 Market CapDay's VolumeLast TradeChange
 -0$0.0010.0%
 
NASDAQ:ONXXONYX PHARM
 Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company engaged in developing therapies that target the molecular mechanisms that cause cancer. With the Company’s collaborators, the Company is developing anticancer therapies. The Company’s product, Nexavar (sorafenib) tablets, being developed with the Company’s collaborator Bayer HealthCare Pharmaceuticals (Bayer), is approved by the United States Food and Drug Administration (FDA), for advanced kidney cancer and liver cancer. Nexavar is an orally available kinase and angiogenesis inhibitor and is one of a new class of anticancer treatments that target both cancer cell proliferation and tumor growth through the inhibition of key signaling pathways. As of December 31, 2008, Nexavar was approved in more than 70 countries for the treatment of advanced kidney cancer and in more than 60 countries for the treatment of liver cancer.
 Market CapDay's VolumeLast TradeChange
 -1,695,959$26.77+0.4502%
 
OTC PK:OCHTOrchestra Therapeutics, Inc.
 Orchestra Therapeutics is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. Co.'s lead immune-based therapeutic product candidate is NeuroVax? for the treatment of multiple sclerosis (MS). In addition, Co. has two product candidates, Remune and IR103 , for the treatment of Human Immunodeficiency Virus (HIV). NeuroVax? is based on Co.'s patented T-cell receptor (TCR) peptide vaccine technology. In addition to MS, Co. has open Investigational New Drug Applications with the U.S. FDA for clinical evaluation of TCR peptide-based immune-based therapies for rheumatoid arthritis and psoriasis.
 Market CapDay's VolumeLast TradeChange
 -208$0.030.0%
 
NASDAQ:ORCHORCHID CELLMARK
 Orchid Cellmark is engaged in providing deoxyribonucleic acid (DNA) testing services that generate genetic profile information by analyzing an organism's unique genetic identity. Co.'s business is focused on DNA testing for human identity as well as for animal and agricultural applications. In the human identity area, Co. provides DNA testing services for forensic, family relationship and security applications. In agricultural applications, Co. provides DNA testing services for food safety and selective trait breeding. Co. provides its DNA testing services to government agencies, private individuals and commercial companies primarily in the U.S. and the U.K.
 Market CapDay's VolumeLast TradeChange
 $98M21,458$1.56+2.6315%
 
OTC PK:ORXEOre Pharmaceutical Holdings, Inc.
 Ore Pharmaceuticals provides pharmaceutical development services that enables it to uncover new development paths for drug candidates provided by its customers, for which development has been discontinued. Co. operates its business through two business segments: the Drug Repositioning Division and the Genomics Division. Co.'s Drug Repositioning Division is a pharmaceutical development division that identifies and develops new or expanded uses for small molecule therapeutics. Co.'s Genomics division consists of proprietary reference gene expression and toxicogenomics databases, toxicogenomics services, software tools, microarray data generation and analysis and other services
 Market CapDay's VolumeLast TradeChange
 -0$0.4010.0%
 
NASDAQ:OSCIOSCIENT PHARMA
 Oscient Pharmaceuticals is a biopharmaceutical company engaged in selling and marketing products to community-based primary care physicians. As of Dec 31 2006, Co. marketed two U.S. Food and Food and Drug Administration (FDA)-approved products with its primary care sales force: ANTARA (fenofibrate) capsules and FACTIVE (gemifloxacin mesylate) tablets. ANTARA is approved by the FDA to treat hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with a healthy diet. FACTIVE is indicated for the treatment of community-acquired pneumonia of mild to moderate severity (CAP) and acute bacterial exacerbations of chronic bronchitis (AECB).
 Market CapDay's VolumeLast TradeChange
 -0$0.0510.0%
 
NASDAQ:OSIPOSI PHARMACEUTICALS
 OSI Pharmaceuticals is a biotechnology company that discovers, develops and commercializes molecular targeted therapies, addressing unmet medical needs in oncology, diabetes and obesity. Co.'s flagship product, Tarceva?, is an oral, once-a-day, small molecule inhibitor of the epidermal growth factor receptor (HER1/EGFR), the treatment of advanced non-small cell lung cancer patients who have failed at least one prior chemotherapy regimen, and for the treatment of patients with locally advanced and metastatic pancreatic cancer in combination with the gemcitabine. Co. co-promotes Tarceva in the U.S. with Genentech, Inc. and receives royalties on sales from its international partner, Roche.
 Market CapDay's VolumeLast TradeChange
 -0$57.490.0%
 
NASDAQ:OSIROSIRIS THERAPEUTICS
 Osiris Therapeutics is a stem cell therapeutic company that develops and markets products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. As at Dec 31 2006, Co. had one commercially available product in the U.S., Osteocel , for regenerating bone in orthopedic indications that utilize human mesenchymal stem cells; and three biologic drug candidates: Prochymal , for the treatment of inflammatory disease, Chondrogen , for regenerating cartilage in the knee, and Provacel , for repairing heart tissue following a heart attack. Also, Co. had developed an intellectual property that includes 47 U.S. and 167 foreign patents owned or licensed at Dec 31 2006.
 Market CapDay's VolumeLast TradeChange
 -29,351$7.55-3.3291%
 
NASDAQ:OXGNOXIGENE
 OxiGene is a biotechnology company engaged in developing small-molecule therapeutics to treat cancer and certain eye diseases. Co.'s focus is the development and commercialization of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. As of Dec 31 2006, Co. had two therapeutic product candidates in clinical and preclinical development. Co.'s lead clinical compound is Combretastatin A4P , which is being evaluated in multiple ongoing clinical trials in various oncology and ophthalmic indications.
 Market CapDay's VolumeLast TradeChange
 -487,467$0.3397+2.6283%
 
OTCBB:PBMEPacific Biometrics, Inc.
 Pacific Biometrics provides specialty central laboratory services to support pharmaceutical and laboratory diagnostic manufacturers in the conduct of human clinical research, for use in their drug and diagnostic product development efforts. Co.'s clients include a number of multi-national pharmaceutical, biotechnology and diagnostic companies. Co.'s specialty areas include cardiovascular disease, diabetes, and bone and joint diseases. Co. also has central laboratory capability and provides full-service central laboratory support for multi-center clinical trials, including routine safety lab tests (general chemistry, hematology, and urinalysis).
 Market CapDay's VolumeLast TradeChange
 $10M0$0.560.0%
 
NYSE:PTNPalatin Technologies, Inc.
 Palatin Technologies is a biopharmaceutical company focusing on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Therapeutics affecting the activity of the melanocortin family of receptors may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, cachexia (extreme wasting, generally secondary to a chronic disease), skin pigmentation disorders and inflammation-related diseases. Co. focuses its efforts on the following products and development programs: erectile dysfunction and female sexual dysfunction-bremelanotide, obesity, congestive heart failure, and NeutroSpec .
 Market CapDay's VolumeLast TradeChange
 -1,874,913$0.2099+6.5482%
 
More Pages: Page: 1 2 3 4 5 6 (7) 8 9 10 11
More

The term Market Sector is used to describe a set of businesses that are buying and selling such similar goods and services that they are in direct competition with each other. Analysts divide the stock market itself into market sectors so that shares of companies that are in direct competition are listed alongside each other.

In the bond market it refers to the division of the market by the type of issuer. E.g. government, state, corporate, or utility.

Markets are split into sectors using the Global Industry Classification Standard.

Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright © 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts